Home > Insider Trading > Filing (0000899243-19-017480)

Filing Details

Accession Number:: 0000899243-19-017480
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-06-19 18:52:17
Reporting Period:: 2019-06-17

Accepted Time:: 2019-06-19 18:52:17
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1740547	Urovant Sciences Ltd.	UROV	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1290166	Qvt Associates Gp Llc	444 Madison Avenue, 21St Floor New York NY 10022		No	No	Yes	No
1771138	Ltd. Cayman Investment Financial Qvt	190 Elgin Avenue George Town, Grand Cayman E9 KY1-9005		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares, Par Value $0.000037453 Per Share	Acquisiton	2019-06-17	6,541	$8.53	22,848,350	No	4	P	Indirect	(see fn5)
Common Shares, Par Value $0.000037453 Per Share	Acquisiton	2019-06-18	6,706	$8.21	22,855,056	No	4	P	Indirect	(see fn5)
Common Shares, Par Value $0.000037453 Per Share	Acquisiton	2019-06-19	4,957	$8.17	22,860,013	No	4	P	Indirect	(see fn5)

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	(see fn5)
No	4	P	Indirect	(see fn5)
No	4	P	Indirect	(see fn5)

Footnotes

The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the "Exchange Act") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act.
The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.11 to $8.70, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. ("Urovant"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.09 to $8.29, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.00 to $8.27, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4.
QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,860,013 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein.